Benzinga's Top #PreMarket Losers

shares fell 74.49 percent to $3.49 in pre-market trading on the failed CUPID2 trial of MYDICAR in advanced heart failure.

fell 13.32 percent to $47.88 in pre-market trading following the report of overstatement of revenue and downgrade. The company said it will make additional accounting restatements that will reduce previously reported revenue for the final three quarters of 2014. Piper Jaffray downgraded Akorn from Overweight to Neutral.

shares dropped 6.79 percent to $20.32 in pre-market following the announcement of termination of business combination agreement with TOKYO ELECTRON LTD

.

slipped 4.72 percent to $13.63 in pre-market trading. Marvell Technology said Q1 revenue will be below its earlier forecast.

shares declined 3.97 percent to $32.90 in pre-market trading on the announcement of business strategy. Deutsche Bank will spinoff Postbank branches in Germany via IPO.